HVE Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
High Cash GenerationConsistently strong operating and free cash flow indicate durable earnings quality and internal funding for R&D, acquisitions, or dividends. High cash conversion limits reliance on external financing and supports strategic flexibility over the next 2–6 months and beyond.
De-risked Balance SheetMaterial debt reduction and a larger equity base strengthen solvency and lower refinancing risk, improving financial flexibility. This makes the company better positioned to fund pipeline development or opportunistic investments without stressing liquidity.
Strategic Diversification: LYNX And Licensing DealsOwning the LYNX platform and launching Nortiva creates a durable product-development avenue beyond royalties. Combined with licensing deals (e.g., Dr. Reddy’s for XACDURO), this expands addressable markets and creates multiple, long‑term commercial and milestone revenue streams.
Bears Say
Earnings VolatilityLarge swings in margins suggest earnings are influenced by non‑recurring items or timing of investment gains, making forward cash flows less predictable. This undermines near‑term planning for capital allocation and could affect sustained payout or reinvestment policies.
Concentrated Royalty RelianceReliance on royalties from a few partnered respiratory franchises concentrates revenue risk. Long‑term cash generation depends on partners' commercialization, formulary access, and competitive dynamics, which Innoviva cannot fully control.
Historical Leverage Variability & Data InconsistencyPast elevated leverage cycles plus inconsistencies in reported leverage metrics increase uncertainty about financial resilience under stress. This can complicate credit planning and raise refinancing or covenant risk during adverse periods.
Innoviva News
HVE FAQ
What was Innoviva Inc’s price range in the past 12 months?
Currently, no data Available
What is Innoviva Inc’s market cap?
Innoviva Inc’s market cap is CHF1.23B.
When is Innoviva Inc’s upcoming earnings report date?
Innoviva Inc’s upcoming earnings report date is Nov 11, 2026 which is in 84 days.
How were Innoviva Inc’s earnings last quarter?
Innoviva Inc released its earnings results on Aug 05, 2026. The company reported -CHF0.923 earnings per share for the quarter, missing the consensus estimate of CHF0.353 by -CHF1.276.
Is Innoviva Inc overvalued?
According to Wall Street analysts Innoviva Inc’s price is currently Undervalued.
Does Innoviva Inc pay dividends?
Innoviva Inc does not currently pay dividends.
What is Innoviva Inc’s EPS estimate?
Innoviva Inc’s EPS estimate is 0.41.
How many shares outstanding does Innoviva Inc have?
Innoviva Inc has 72,245,480 shares outstanding.
What happened to Innoviva Inc’s price movement after its last earnings report?
Innoviva Inc reported an EPS of -CHF0.923 in its last earnings report, missing expectations of CHF0.353. Following the earnings report the stock price went same N/A.
Which hedge fund is a major shareholder of Innoviva Inc?
Currently, no hedge funds are holding shares in CH:HVE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Innoviva Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
CHF33.02 (― Upside)
CHF33.02 (― Upside)
Blogger Sentiment
Bullish
CH:HVE Sentiment 67%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.31%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
27.68%
Trailing 12-Months
Company Description
Innoviva Inc
Innoviva, Inc. functions as a pharmaceutical company, concentrating on the worldwide creation and marketing of medical treatments. Its current product lineup prominently includes several once-daily combination therapies: RELVAR/BREO ELLIPTA, which integrates vilanterol (a long-acting beta2 agonist, or LABA) with fluticasone furoate (an inhaled corticosteroid, or ICS); ANORO ELLIPTA, a medication that pairs umeclidinium bromide (a long-acting muscarinic antagonist, or LAMA) with vilanterol (LABA); and TRELEGY ELLIPTA, a comprehensive treatment combining an ICS, LAMA, and LABA. The company has forged a key strategic alliance with Sarissa Capital Management LP. Moreover, Innoviva collaborates with Glaxo Group Limited under an agreement focused on the development and commercialization of daily LABA-based products designed to treat chronic obstructive pulmonary disease and asthma. Founded in 1996, the corporation was initially known as Theravance, Inc., before officially changing its name to Innoviva, Inc. in January 2016. Its primary operational base is situated in Burlingame, California.